Physician profile
Daniel John Groth
NPI 1821476979
$2,271.53
in general payments reported to CMS, 2019-2025
19 companies · $923 in 2025
The $923 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $253 · 2022: $175 · 2023: $211 · 2024: $709 · 2025: $923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,603 · Education: $195 · Consulting Fee: $45.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,603.16 |
| Education | $194.94 |
| Consulting Fee | $45.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $921.43 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Genzyme Corporation | $259.35 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $194.94 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $179.37 | 2023-2025 | Cuvitru, Takhzyro, Eohilia |
| Regeneron Healthcare Solutions, INC. | $119.47 | 2024-2025 | Dupixent |
| Amgen INC. | $111.97 | 2023-2025 | Tezspire |
| Glaxosmithkline, LLC. | $67.85 | 2024-2025 | Nucala |
| Biocryst US Sales Co., LLC | $56.25 | 2025 | Orladeyo |
| Alk-Abello, INC | $54.30 | 2023-2025 | Odactra, Grastek, Ragwitek |
| Ars Pharmaceuticals Operations, INC. | $49.43 | 2025 | Neffy |
| Adma Biomanufacturing LLC | $45.16 | 2024-2025 | |
| Pfizer INC. | $44.68 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $32.90 | 2025 | |
| Grifols USA, LLC | $27.37 | 2025 | Xembify |
| Lilly USA, LLC | $27.35 | 2025 | Ebglyss |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $24.70 | 2025 | Ayvakit |
| Pharming Healthcare, INC. | $22.34 | 2025 | Ruconest |
| Organon LLC | $20.50 | 2025 | Vtama |
| Kaleo, INC. | $12.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Groth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.